Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma Positive opinion from the European Patent Office ...

Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, ...

Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 clinical study of its oral drug candidate soquelitinib in atopic ...

A new study published in the Journal of the European Academy of Dermatology & Venerology showed that in children with severe ...

Winters are known to worsen symptoms of eczema due to dropping temperatures.It is believed that around 8 million people in ...

If you experience chronic dry, itchy and red skin, you may be one of the millions of Americans with eczema. The National Eczema Association reports that an estimated 10% of the world population ...

Experts break down the most important facts about atopic dermatitis on the hands, including risk factors, treatments, and tips for soothing relief. Atopic dermatitis (AD), the most common form of ...